The University of Oxford will hold a workshop on 28-29 May to provide an introduction to protein crystallography and the use of high-resolution protein structures for rational drug development.
The main purpose of the lectures is to give a comprehensive overview describing the theoretical background that covers the entire process.
This covers the generation of highly purified recombinant proteins for crystallisation, the structure-determination process using x-ray crystallography and the interpretation of structural information, including its use in designing specific inhibitors.
The course is led by Stefan Knapp, professor of structural chemistry at the Structural Genomics Consortium in the Nuffield Department of Medicine at the University of Oxford.
Founded by David Kerr, professor of clinical pharmacology and cancer therapeutics at Oxford, the two-year part-time modular Masters and one-week intensive courses provide clinicians and health and pharmaceutical professionals from the UK and overseas with training in the principles underpinning clinical research and the skills to translate these into high-quality clinical and research practice.
The MSc in Experimental Therapeutics is a part-time programme consisting of eight taught modules and a dissertation.
Some of the modules provide students with the necessary knowledge for qualifications from the Royal Society of Medicine's Faculty of Pharmaceutical Medicine.
